Advanced

Randomised controlled trial for emphysema with a selective agonist of the gamma-type retinoic acid receptor

Stolk, Jan; Stockley, Robert A.; Stoel, Berend C.; Cooper, Brendan G.; Piitulainen, Eeva LU ; Seersholm, Niels; Chapman, Kenneth R.; Burdon, Jonathan G. W.; Decramer, Marc and Abboud, Raja T., et al. (2012) In European Respiratory Journal 40(2). p.306-312
Abstract
Palovarotene is an oral gamma-selective retinoid agonist. In animal emphysema models, palovarotene reduced inflammation, promoted structural repair and functional improvement. REPAIR (Retinoid treatment of Emphysema in Patients on the alpha(1)-antitrypsin International Registry), was an investigator-initiated, double-blind, placebo-controlled randomised study to assess the safety and efficacy of 5 mg.day(-1) palovarotene given for 1 year to 262 patients with severe alpha(1)-antitrypsin deficiency and emphysema confirmed by computed tomography. Change in volume-adjusted 15th percentile point lung density from baseline in 1 year was the primary endpoint; functional end-points were also regularly assessed. We randomly assigned 133 and 129... (More)
Palovarotene is an oral gamma-selective retinoid agonist. In animal emphysema models, palovarotene reduced inflammation, promoted structural repair and functional improvement. REPAIR (Retinoid treatment of Emphysema in Patients on the alpha(1)-antitrypsin International Registry), was an investigator-initiated, double-blind, placebo-controlled randomised study to assess the safety and efficacy of 5 mg.day(-1) palovarotene given for 1 year to 262 patients with severe alpha(1)-antitrypsin deficiency and emphysema confirmed by computed tomography. Change in volume-adjusted 15th percentile point lung density from baseline in 1 year was the primary endpoint; functional end-points were also regularly assessed. We randomly assigned 133 and 129 patients to placebo or palovarotene, respectively. Both groups were well matched for all baseline characteristics, including respiratory medications. 88% and 85% of patients completed 1 year of treatment with placebo and palovarotene, respectively. Palovarotene was generally well tolerated. In the study completers population, the placebo-corrected difference of lung density was -0.45 HU at week 28 (p=0.64) and -0.25 HU at week 52 (p=0.94). A nonsignificant treatment difference in most functional parameters of the lung in favour of the drug was observed over time suggesting potential pharmacological effects of palovarotene. Palovarotene 5 mg.day(-1) over 1 yr failed to show a significant benefit on lung density in moderate-to-severe emphysema secondary to severe alpha(1)-antitrypsin deficiency. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
alpha(1)-antitrypsin, chronic obstructive pulmonary disease treatment, clinical trials, densitometry, emphysema, retinoids
in
European Respiratory Journal
volume
40
issue
2
pages
306 - 312
publisher
Eur Respiratory Soc
external identifiers
  • wos:000307291700007
  • scopus:84864770563
ISSN
1399-3003
DOI
10.1183/09031936.00161911
language
English
LU publication?
yes
id
19112aac-2bde-4766-86bc-5e59a404fb04 (old id 3151929)
date added to LUP
2012-11-01 09:35:09
date last changed
2017-11-12 03:07:26
@article{19112aac-2bde-4766-86bc-5e59a404fb04,
  abstract     = {Palovarotene is an oral gamma-selective retinoid agonist. In animal emphysema models, palovarotene reduced inflammation, promoted structural repair and functional improvement. REPAIR (Retinoid treatment of Emphysema in Patients on the alpha(1)-antitrypsin International Registry), was an investigator-initiated, double-blind, placebo-controlled randomised study to assess the safety and efficacy of 5 mg.day(-1) palovarotene given for 1 year to 262 patients with severe alpha(1)-antitrypsin deficiency and emphysema confirmed by computed tomography. Change in volume-adjusted 15th percentile point lung density from baseline in 1 year was the primary endpoint; functional end-points were also regularly assessed. We randomly assigned 133 and 129 patients to placebo or palovarotene, respectively. Both groups were well matched for all baseline characteristics, including respiratory medications. 88% and 85% of patients completed 1 year of treatment with placebo and palovarotene, respectively. Palovarotene was generally well tolerated. In the study completers population, the placebo-corrected difference of lung density was -0.45 HU at week 28 (p=0.64) and -0.25 HU at week 52 (p=0.94). A nonsignificant treatment difference in most functional parameters of the lung in favour of the drug was observed over time suggesting potential pharmacological effects of palovarotene. Palovarotene 5 mg.day(-1) over 1 yr failed to show a significant benefit on lung density in moderate-to-severe emphysema secondary to severe alpha(1)-antitrypsin deficiency.},
  author       = {Stolk, Jan and Stockley, Robert A. and Stoel, Berend C. and Cooper, Brendan G. and Piitulainen, Eeva and Seersholm, Niels and Chapman, Kenneth R. and Burdon, Jonathan G. W. and Decramer, Marc and Abboud, Raja T. and Mannes, Gregorius P. M. and Wouters, Emiel F. and Garrett, Jeffrey E. and Barros-Tizon, Juan C. and Russi, Erich W. and Lomas, David A. and MacNee, William A. and Rames, Alexis},
  issn         = {1399-3003},
  keyword      = {alpha(1)-antitrypsin,chronic obstructive pulmonary disease treatment,clinical trials,densitometry,emphysema,retinoids},
  language     = {eng},
  number       = {2},
  pages        = {306--312},
  publisher    = {Eur Respiratory Soc},
  series       = {European Respiratory Journal},
  title        = {Randomised controlled trial for emphysema with a selective agonist of the gamma-type retinoic acid receptor},
  url          = {http://dx.doi.org/10.1183/09031936.00161911},
  volume       = {40},
  year         = {2012},
}